Blog Exposure – PerkinElmer to Takeover Australian Biotech Company RHS Ltd

Stock Monitor: BioTelemetry Post Earnings Reporting

LONDON, UK / ACCESSWIRE / February 28, 2018 / Active-Investors.com has just released a free research report on PerkinElmer, Inc. (NYSE: PKI). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PKI as the Company’s latest news hit the wire. On February 26, 2018, RHS Ltd announced that PerkinElmer has entered into a Scheme Implementation Agreement (SIA) wherein PerkinElmer will acquire all outstanding shares of RHS at $0.28 per share in cash. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for BioTelemetry, Inc. (NASDAQ: BEAT), which also belongs to the Healthcare sector as the Company PerkinElmer. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=BEAT

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, PerkinElmer most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=PKI

The SIA has been vetted and approved by the Board of Directors of RHS as the deal would create great value for its shareholders and be in the best interest of the Company. RHS’ Board also believes that the deal with PerkinElmer would allow it to grow in a manner which not be possible on a standalone basis.

Commenting on the proposal from PerkinElmer, Dr. David Brookes, Chairman of RHS, said:

“The PKI proposal was welcomed by the Board as an opportune time to reward shareholder loyalty and to progress RHS’ capabilities and technologies at an important commercial inflection point.”

Dr Michelle Fraser, CEO of RHS, stated:

“The offer from PKI reinforces the considerable expertise that the RHS team have integrated into each of our products. Bringing RHS and PKI together provides an opportunity for our products to reach the clinical and applied research markets through a large and highly experienced global team.”

Terms of the SIA

RHS has 89,920,483 outstanding shares, which PerkinElmer has offered to acquire at $0.28 per share in cash. The offer price is at a 100% premium of RHS’s closing price of $0.14 per share on February 23, 2018, the last trading day before the deal was announced. Board members who have shareholding in the Company have agreed to vote in favor of the deal. The deal is subject to a report from an independent expert who will confirm that PerkinElmer’s offer is in the best interest of RHS’s shareholders.

The SIA will be implemented as per a Court approved scheme under the Australian Corporations Act. The deal also requires the approval from majority RHS’s shareholders, The Australian Securities and Investments Commission (ASIC), The Australian Securities Exchange (ASX) for the implementation of the SIA. The SIA also provides for a termination fee if RHS receives a superior proposal. RHS has scheduled a meeting of its shareholders on May 22, 2018, to undertake voting on the matter. It is estimated that the first Court hearing would be scheduled on April 12, 2018, where RHS will get approval for the SIA and documentation to be shared with its shareholders. The final Court hearing for the approval of the SIA is estimated to be on May 25, 2018. The actual implementation of the SIA is expected to be on June 11, 2018. However, these dates are subject to change and based on the availability of Court dates.

PerkinElmer and RHS have also reached an understanding with regards to outstanding options of RHS. PerkinElmer has agreed to enter into separate agreements with the holders of these options to acquire all the outstanding options of RHS, which is a total of 7,400,000 at offer price ranging from $0.20 to the difference in option strike price. If PerkinElmer is unable to acquire the options, RHS has offered to plan for the acquisition of the same.

RHS has opted to raise funds with a max limit of $750,000 from The Very Company, an entity belonging to RHS Alternative Director Colin Matthews. The funding is at a 9% interest rate with repayment date of September 28, 2018. RHS plans to utilize these funds to complete the deal and for business purposes in the interim period of the acquisition. This facility will allow RHS to raise capital without diluting its shareholding before the completion of deal with PerkinElmer.

About RHS Ltd

Adelaide, South Australia-based RHS is a developer of advanced patented single cell genomic technologies focussed on improving the health and research outcomes, based on deep technical experience in the field. DOPlify® is a platform product for whole genome amplification (WGA) of single or small numbers of cells. DOPlify® is applicable to the global Next Generation Sequencing (NGS) market. PG-Seq™, RHS’ NGS workflow and EmbryoCellect®, RHS’ microarray workflow, both incorporate DOPlify® and have been specifically designed for the genetic screening of IVF embryos.

About PerkinElmer, Inc.

Waltham, Massachusetts-based PerkinElmer is a global leader committed to innovating for a healthier world. The Company provides solutions for critical issues especially impacting the diagnostics, discovery, and analytical solutions markets. The Company’s innovative detection, imaging, informatics, and service capabilities combined with deep market knowledge and scientific expertise, help customers gain earlier and more accurate insights to improve lives. The Company has presence in over 150 countries and is supported by a team of 11,000 employees.

PerkinElmer’s revenues for FY17 was approximately $2.3 billion.

Stock Performance Snapshot

February 27, 2018 – At Tuesday’s closing bell, PerkinElmer’s stock dropped 1.18%, ending the trading session at $76.95.

Volume traded for the day: 743.64 thousand shares, which was above the 3-month average volume of 671.63 thousand shares.

Stock performance in the last three-month – up 4.89%; previous six-month period – up 17.75%; past twelve-month period – up 39.93%; and year-to-date – up 5.24%

After yesterday’s close, PerkinElmer’s market cap was at $8.46 billion.

Price to Earnings (P/E) ratio was at 54.42.

The stock has a dividend yield of 0.36%.

The stock is part of the Healthcare sector, categorized under the Medical Laboratories & Research industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 491160